The Food and Drug Administration (FDA) is concerned about the potential for misdiagnosis of Lyme disease based on the results of commonly marketed tests for detecting antibodies to Borrelia burgdorferi, the organism that causes Lyme disease. It is important that clinicians understand that a positive test result does not necessarily indicate current infection with B. burgdorferi, and a patient with active Lyme disease may have a negative test result. (1-5) The tests should be used only to support a clinical diagnosis of Lyme disease and should never be the primary basis for making diagnostic or treatment decisions. Diagnosis should be based on a patient history, which includes symptoms and exposure to the tick vector and physical findings. The most definitive diagnostic procedure is biopsy and isolation of B. burgdorferi in culture.
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Assays for anti-Borrelia burgdorferi (anti-Bb) can provide evidence of previous or current infection, but to improve reliability FDA supports the Centers for Disease Control and Prevention (CDC) recommendation for two-step testing and interpretation of results (1).
The first step is to perform an assay that detects either total or class-specific antibodies (IgM or IgG) by using enzyme-linked immunosorbent technology ("ELISA" or "EIA") or indirect immunofluorescence microscopy ("IFA"). IgM levels usually peak 3 to 6 weeks after infection. IgG antibodies begin to be detectable several weeks after infection and may continue to develop for several months and generally persist for years.
• A negative result indicates only that there was no serologic evidence of infection with B. burgdorferi. It should not be used as the basis for excluding B. burgdorferi as the cause of illness, especially if the blood was collected within 2 weeks of when symptoms began.
• A positive or equivocal result is presumptive evidence of the presence of anti-Bb.
It should always be followed by second-step testing and should not be reported until the second step testing is completed.
The second step is to perform a Western-blot (immunoblot) assay, a more specific assay than that used for the first step Even using the two-step approach, the sensitivity and specificity of the combined test results are inadequate. Because assays for anti-Bb should be used only for supporting a clinical diagnosis of Lyme disease and not for "screening" asymptomatic individuals, the result of the first-step assay is best described as "initial" rather than "screening." Likewise, the second-step Western-blot assay is best described as "supplemental" rather than "confirmatory", because of the low specificity for detecting IgM anti-Bb. Thus, a positive IgM anti-Bb result alone is not adequate for supporting a diagnosis of Lyme disease in persons with illness of greater than one-month duration.
Several factors contribute to the limitations of using ELISA, IFA, or Western blot tests for supporting a diagnosis of Lyme disease. In summary, serologic testing is not useful early in the course of Lyme disease, because of the low sensitivity of tests in early disease. Serologic testing may be more useful in later disease at which time sensitivity and specificity of the test is improved.
